Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
Public ClinicalTrials.gov record NCT04221893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Study identification
- NCT ID
- NCT04221893
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- University of California, San Francisco
- Other
- Enrollment
- 28 participants
Conditions and interventions
Conditions
- Metastatic Anal Canal Carcinoma
- Metastatic Colorectal Carcinoma
- Metastatic Esophageal Carcinoma
- Metastatic Gastric Carcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Hepatocellular Carcinoma
- Metastatic Malignant Digestive System Neoplasm
- Metastatic Small Intestinal Carcinoma
- Pancreatobiliary Carcinoma
- Pathologic Stage IV Gastric Cancer AJCC v8
- Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
- Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
- Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8
- Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8
- Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Stage IV Adenocarcinoma of the Gastroesophageal Junction
- Stage IV Anal Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Esophageal Adenocarcinoma
- Stage IV Esophageal Squamous Cell Carcinoma
- Stage IV Gastric Cancer
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IVA Adenocarcinoma of the Gastroesophageal Junction
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVA Esophageal Adenocarcinoma
- Stage IVA Esophageal Squamous Cell Carcinoma
- Stage IVA Gastric Cancer
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVB Esophageal Adenocarcinoma
- Stage IVB Esophageal Squamous Cell Carcinoma
- Stage IVB Gastric Cancer
- Stage IVB Gastroesophageal Junction Adenocarcinoma
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Stage IVC Colorectal Cancer AJCC v8
Interventions
- Radiation Therapy (RT) Radiation
Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 6, 2020
- Primary completion
- Jun 29, 2026
- Completion
- Apr 29, 2028
- Last update posted
- Oct 5, 2025
2020 – 2028
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | Recruiting |
| John Muir Medical Center-Walnut Creek | Walnut Creek | California | 94598 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04221893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2025 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04221893 live on ClinicalTrials.gov.